Nadine E Halko, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 701 N Broadway, Sleepy Hollow, NY 10591 Phone: 914-366-3557 Fax: 914-366-1557 |
Vivek Venkatakrishnan, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 701 N Broadway, Sleepy Hollow, NY 10591 Phone: 914-366-3557 |
Dr. Trevor Bhullar Gill, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 701 N Broadway, Sleepy Hollow, NY 10591 Phone: 914-366-3000 |
Dr. Michael Marchese, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 701 N Broadway, Phelps Memorial Hospital Center, Sleepy Hollow, NY 10591 Phone: 914-366-1179 Fax: 914-366-1657 |
Vijaya Sukumar, M.D. Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 701 N Broadway, Sleepy Hollow, NY 10591 Phone: 914-366-3557 Fax: 914-366-1557 |
News Archive
New research released today shows teenagers respond differently to drugs than adults and explores the long-lasting effects of drug use on brain development. One study shows people who start using drugs at a young age have greater cognitive shortfalls, including mental flexibility. Animal studies also suggest adolescents are more susceptible to lower doses of cocaine, are willing to work more for a cocaine "fix" than adults, and are at risk of developing compromised stress responses.
Fujitsu Laboratories Ltd. announced the development of a technology that accelerates database analyses of the correlations between genomic variations and environmental information, such as disease and lifestyle habits. This technology speeds up the process by a factor of roughly 400 compared to existing methods.
By considering molecular-level events on a broader scale, researchers now have a clearer, if more complicated, picture of how one class of immune cells goes wrong when loaded with cholesterol. The findings reported in the February 3rd issue of Cell Metabolism, a Cell Press publication, show that, when it comes to the development of atherosclerosis and heart disease, it's not about any one bad actor-it's about a network gone awry.
AVANIR Pharmaceuticals, Inc. today announced the presentation of detailed data, including safety and tolerability data from the open-label extension as well as cardiac safety data from the double-blind phase of the Phase III confirmatory STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of pseudobulbar affect (PBA). The data were presented in two posters at the American Academy of Neurology (AAN) Annual Meeting in Toronto, Canada.
Long-term dialysis patients undergoing general surgical procedures have a significantly increased risk for postoperative complications and death within 30 days of surgery compared with their nondialysis counterparts, study findings show.
› Verified 5 days ago